Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapine.

Mier D, Schirmbeck F, Stoessel G, Esslinger C, Rausch F, Englisch S, Eisenacher S, de Haan L, Meyer-Lindenberg A, Kirsch P, Zink M.

Eur Arch Psychiatry Clin Neurosci. 2018 Dec 11. doi: 10.1007/s00406-018-0965-4. [Epub ahead of print]

PMID:
30539230
2.

Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression: Results From the AGOPSYCH Study.

Englisch S, Jung HS, Eisenacher S, Lewien A, Becker A, Nowak U, Braun H, Thiem J, Meyer-Lindenberg A, Zink M.

J Clin Psychopharmacol. 2018 Aug;38(4):357-361. doi: 10.1097/JCP.0000000000000909.

PMID:
29912792
3.

Response to Agomelatine Treatment is Independent of Smoking Status and Dosage: Results From the AGOPSYCH Study.

Englisch S, Jung HS, Lewien A, Becker A, Nowak U, Braun H, Eisenacher S, Thiem J, Meyer-Lindenberg A, Zink M.

Pharmacopsychiatry. 2019 Mar;52(3):142-146. doi: 10.1055/a-0606-5240. Epub 2018 May 7.

PMID:
29734455
4.

Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study.

Englisch S, Jung HS, Lewien A, Becker A, Nowak U, Braun H, Thiem J, Eisenacher S, Meyer-Lindenberg A, Zink M.

J Clin Psychopharmacol. 2016 Dec;36(6):597-607.

PMID:
27805978
5.

Aberrant activity and connectivity of the posterior superior temporal sulcus during social cognition in schizophrenia.

Mier D, Eisenacher S, Rausch F, Englisch S, Gerchen MF, Zamoscik V, Meyer-Lindenberg A, Zink M, Kirsch P.

Eur Arch Psychiatry Clin Neurosci. 2017 Oct;267(7):597-610. doi: 10.1007/s00406-016-0737-y. Epub 2016 Oct 21.

PMID:
27770284
6.

Fast sleep spindle reduction in schizophrenia and healthy first-degree relatives: association with impaired cognitive function and potential intermediate phenotype.

Schilling C, Schlipf M, Spietzack S, Rausch F, Eisenacher S, Englisch S, Reinhard I, Haller L, Grimm O, Deuschle M, Tost H, Zink M, Meyer-Lindenberg A, Schredl M.

Eur Arch Psychiatry Clin Neurosci. 2017 Apr;267(3):213-224. doi: 10.1007/s00406-016-0725-2. Epub 2016 Aug 26.

PMID:
27565806
7.

Early cognitive basic symptoms are accompanied by neurocognitive impairment in patients with an 'at-risk mental state' for psychosis.

Eisenacher S, Rausch F, Ainser F, Englisch S, Becker A, Mier D, Fenske S, Meyer-Lindenberg A, Kirsch P, Zink M.

Early Interv Psychiatry. 2018 Aug;12(4):586-595. doi: 10.1111/eip.12350. Epub 2016 May 12.

PMID:
27169782
8.

Evaluation of the 'Jumping to conclusions' bias in different subgroups of the at-risk mental state: from cognitive basic symptoms to UHR criteria.

Rausch F, Eisenacher S, Elkin H, Englisch S, Kayser S, Striepens N, Lautenschlager M, Heinz A, Gudlowski Y, Janssen B, Gaebel W, Michel TM, Schneider F, Lambert M, Naber D, Juckel G, Krueger-Oezguerdal S, Wobrock T, Hasan A, Riedel M, Moritz S, Müller H, Klosterkötter J, Bechdolf A, Zink M, Wagner M.

Psychol Med. 2016 Jul;46(10):2071-81. doi: 10.1017/S0033291716000465. Epub 2016 Apr 20.

PMID:
27094404
9.

Bias against disconfirmatory evidence in the 'at-risk mental state' and during psychosis.

Eisenacher S, Rausch F, Mier D, Fenske S, Veckenstedt R, Englisch S, Becker A, Andreou C, Moritz S, Meyer-Lindenberg A, Kirsch P, Zink M.

Psychiatry Res. 2016 Apr 30;238:242-250. doi: 10.1016/j.psychres.2016.02.028. Epub 2016 Feb 17.

PMID:
27086240
10.

Schizophrenia treatment: an obstacle course.

Zink M, Englisch S.

Lancet Psychiatry. 2016 Apr;3(4):310-2. doi: 10.1016/S2215-0366(16)00023-7. Epub 2016 Feb 25. No abstract available.

PMID:
26922476
11.

Investigating the efficacy of an individualized metacognitive therapy program (MCT+) for psychosis: study protocol of a multi-center randomized controlled trial.

Schneider BC, Brüne M, Bohn F, Veckenstedt R, Kolbeck K, Krieger E, Becker A, Drommelschmidt KA, Englisch S, Eisenacher S, Lee-Grimm SI, Nagel M, Zink M, Moritz S.

BMC Psychiatry. 2016 Feb 27;16:51. doi: 10.1186/s12888-016-0756-2.

12.

Investigation of metamemory functioning in the at-risk mental state for psychosis.

Eisenacher S, Rausch F, Ainser F, Mier D, Veckenstedt R, Schirmbeck F, Lewien A, Englisch S, Andreou C, Moritz S, Meyer-Lindenberg A, Kirsch P, Zink M.

Psychol Med. 2015 Nov;45(15):3329-40. doi: 10.1017/S0033291715001373. Epub 2015 Jul 23.

PMID:
26201365
13.

Reduced activation in the ventral striatum during probabilistic decision-making in patients in an at-risk mental state.

Rausch F, Mier D, Eifler S, Fenske S, Schirmbeck F, Englisch S, Schilling C, Meyer-Lindenberg A, Kirsch P, Zink M.

J Psychiatry Neurosci. 2015 May;40(3):163-73.

14.

Metamemory in schizophrenia: retrospective confidence ratings interact with neurocognitive deficits.

Eifler S, Rausch F, Schirmbeck F, Veckenstedt R, Mier D, Esslinger C, Englisch S, Meyer-Lindenberg A, Kirsch P, Zink M.

Psychiatry Res. 2015 Feb 28;225(3):596-603. doi: 10.1016/j.psychres.2014.11.040. Epub 2014 Dec 2.

PMID:
25530415
15.

Overconfidence in incorrect perceptual judgments in patients with schizophrenia.

Moritz S, Ramdani N, Klass H, Andreou C, Jungclaussen D, Eifler S, Englisch S, Schirmbeck F, Zink M.

Schizophr Res Cogn. 2014 Dec 8;1(4):165-170. doi: 10.1016/j.scog.2014.09.003. eCollection 2014 Dec.

16.

Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia.

Schirmbeck F, Mier D, Esslinger C, Rausch F, Englisch S, Eifler S, Meyer-Lindenberg A, Kirsch P, Zink M.

J Psychiatry Neurosci. 2015 Mar;40(2):89-99.

17.

Antipsychotic treatment modulates glutamate transport and NMDA receptor expression.

Zink M, Englisch S, Schmitt A.

Eur Arch Psychiatry Clin Neurosci. 2014 Nov;264 Suppl 1:S67-82. doi: 10.1007/s00406-014-0534-4. Epub 2014 Sep 12. Review.

PMID:
25214389
18.

Neurocognitive capabilities modulate the integration of evidence in schizophrenia.

Eifler S, Rausch F, Schirmbeck F, Veckenstedt R, Englisch S, Meyer-Lindenberg A, Kirsch P, Zink M.

Psychiatry Res. 2014 Sep 30;219(1):72-8. doi: 10.1016/j.psychres.2014.04.056. Epub 2014 May 14.

PMID:
24880580
19.

Reduced activation in ventral striatum and ventral tegmental area during probabilistic decision-making in schizophrenia.

Rausch F, Mier D, Eifler S, Esslinger C, Schilling C, Schirmbeck F, Englisch S, Meyer-Lindenberg A, Kirsch P, Zink M.

Schizophr Res. 2014 Jul;156(2-3):143-9. doi: 10.1016/j.schres.2014.04.020. Epub 2014 May 13.

PMID:
24831391
20.

Obsessive-compulsive symptoms in at-risk mental states for psychosis: associations with clinical impairment and cognitive function.

Zink M, Schirmbeck F, Rausch F, Eifler S, Elkin H, Solojenkina X, Englisch S, Wagner M, Maier W, Lautenschlager M, Heinz A, Gudlowski Y, Janssen B, Gaebel W, Michel TM, Schneider F, Lambert M, Naber D, Juckel G, Krueger-Oezguerdal S, Wobrock T, Hasan A, Riedel M, Müller H, Klosterkötter J, Bechdolf A.

Acta Psychiatr Scand. 2014 Sep;130(3):214-26. doi: 10.1111/acps.12258. Epub 2014 Feb 26.

PMID:
24571191
21.

Risks and benefits of bupropion treatment in schizophrenia: a systematic review of the current literature.

Englisch S, Morgen K, Meyer-Lindenberg A, Zink M.

Clin Neuropharmacol. 2013 Nov-Dec;36(6):203-15. doi: 10.1097/WNF.0b013e3182a8ea04. Review.

PMID:
24201231
22.

Altered phospholipid metabolism in schizophrenia: a phosphorus 31 nuclear magnetic resonance spectroscopy study.

Weber-Fahr W, Englisch S, Esser A, Tunc-Skarka N, Meyer-Lindenberg A, Ende G, Zink M.

Psychiatry Res. 2013 Dec 30;214(3):365-73. doi: 10.1016/j.pscychresns.2013.06.011. Epub 2013 Sep 14.

PMID:
24045051
23.

Stable cognitive deficits in schizophrenia patients with comorbid obsessive-compulsive symptoms: a 12-month longitudinal study.

Schirmbeck F, Rausch F, Englisch S, Eifler S, Esslinger C, Meyer-Lindenberg A, Zink M.

Schizophr Bull. 2013 Nov;39(6):1261-71. doi: 10.1093/schbul/sbs123. Epub 2012 Oct 27.

24.

Differential effects of antipsychotic agents on obsessive-compulsive symptoms in schizophrenia: a longitudinal study.

Schirmbeck F, Rausch F, Englisch S, Eifler S, Esslinger C, Meyer-Lindenberg A, Zink M.

J Psychopharmacol. 2013 Apr;27(4):349-57. doi: 10.1177/0269881112463470. Epub 2012 Oct 24.

PMID:
23095245
25.

Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients.

Esslinger C, Englisch S, Inta D, Rausch F, Schirmbeck F, Mier D, Kirsch P, Meyer-Lindenberg A, Zink M.

Schizophr Res. 2012 Sep;140(1-3):114-21. doi: 10.1016/j.schres.2012.06.025. Epub 2012 Jul 10.

PMID:
22784688
26.

Treatment-resistant Schizophrenia: Evidence-based Strategies.

Englisch S, Zink M.

Mens Sana Monogr. 2012 Jan;10(1):20-32. doi: 10.4103/0973-1229.91588.

27.

Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive-compulsive symptoms induced by second-generation antipsychotic agents.

Schirmbeck F, Nieratschker V, Frank J, Englisch S, Rausch F, Meyer-Lindenberg A, Rietschel M, Zink M.

Psychiatr Genet. 2012 Oct;22(5):245-52. doi: 10.1097/YPG.0b013e328353fbee.

PMID:
22531293
28.

Pregabalin-associated increase of clozapine serum levels.

Englisch S, Alm B, Meyer-Lindenberg A, Zink M.

J Clin Psychopharmacol. 2012 Feb;32(1):127. doi: 10.1097/JCP.0b013e31823f6540. No abstract available.

PMID:
22217943
29.

Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia.

Schönfelder S, Schirmbeck F, Waltereit R, Englisch S, Zink M.

Clin Neuropharmacol. 2011 Nov-Dec;34(6):256-7. doi: 10.1097/WNF.0b013e31823429bd.

PMID:
22104635
30.

Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.

Schirmbeck F, Esslinger C, Rausch F, Englisch S, Meyer-Lindenberg A, Zink M.

Psychol Med. 2011 Nov;41(11):2361-73. doi: 10.1017/S0033291711000419. Epub 2011 Apr 5.

PMID:
21466748
31.

[Polypharmacy in schizophrenia].

Zink M, Englisch S, Meyer-Lindenberg A.

Nervenarzt. 2011 Jul;82(7):853-8. doi: 10.1007/s00115-010-3196-0. German.

PMID:
21165589
32.

Bupropion for depression in schizophrenia.

Englisch S, Inta D, Eer A, Zink M.

Clin Neuropharmacol. 2010 Sep-Oct;33(5):257-9. doi: 10.1097/WNF.0b013e3181f5a5f9.

PMID:
20852411
33.

Quetiapine combined with amisulpride in schizophrenic patients with insufficient responses to quetiapine monotherapy.

Englisch S, Enning F, Grosshans M, Marquardt L, Waltereit R, Zink M.

Clin Neuropharmacol. 2010 Sep-Oct;33(5):227-9. doi: 10.1097/WNF.0b013e3181f0f013.

PMID:
20838213
34.

Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone.

Kuwilsky A, Krumm B, Englisch S, Dressing H, Zink M.

Pharmacopsychiatry. 2010 Aug;43(6):216-20. doi: 10.1055/s-0030-1254089. Epub 2010 Jun 29.

PMID:
20589598
35.

Augmentation with pregabalin in schizophrenia.

Englisch S, Esser A, Enning F, Hohmann S, Schanz H, Zink M.

J Clin Psychopharmacol. 2010 Aug;30(4):437-40. doi: 10.1097/JCP.0b013e3181e5c095.

PMID:
20531222
36.

Bupropion for depression in schizophrenia: a case report.

Englisch S, Esser A, Zink M.

Pharmacopsychiatry. 2010 Jan;43(1):38-9. doi: 10.1055/s-0029-1242818. Epub 2009 Dec 10. No abstract available.

PMID:
20178095
37.

Polypharmacy in schizophrenia.

Zink M, Englisch S, Meyer-Lindenberg A.

Curr Opin Psychiatry. 2010 Mar;23(2):103-11. doi: 10.1097/YCO.0b013e3283366427. Review.

PMID:
20051861
38.

Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole.

Englisch S, Esslinger C, Inta D, Weinbrenner A, Peus V, Gutschalk A, Schirmbeck F, Zink M.

Clin Neuropharmacol. 2009 Jul-Aug;32(4):227-9. doi: 10.1097/WNF.0b013e31819cc8e6.

PMID:
19644230
39.

Aripiprazole for the management of olanzapine-induced weight gain.

Englisch S, Weinbrenner A, Inta D, Zink M.

Pharmacopsychiatry. 2009 Jul;42(4):166-7. doi: 10.1055/s-0029-1202262. Epub 2009 Jul 7. No abstract available.

PMID:
19585397
40.

Risperidone-associated increase in triglyceride levels.

Weinbrenner A, Peus V, Inta D, Englisch S, Zink M.

Am J Psychiatry. 2009 Jan;166(1):113-4. doi: 10.1176/appi.ajp.2008.08081169. No abstract available.

PMID:
19122019
41.

Urinary retention during combined treatment of postpsychotic depression with duloxetine and olanzapine.

Englisch S, Fritzinger M, Zink M.

Clin Neuropharmacol. 2008 Sep-Oct;31(5):307-9. doi: 10.1097/WNF.0b013e318157e462.

PMID:
18836353
42.

Neurobiology confirms psychopathology. On the antagonism of psychosis and obsessive-compulsive syndromes.

Zink M, Englisch S, Dressing H.

Psychopathology. 2008;41(5):279-85. doi: 10.1159/000141922. Epub 2008 Jul 1. Review.

PMID:
18594162
43.

Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial.

Englisch S, Knopf U, Scharnholz B, Kuwilsky A, Deuschle M, Zink M.

J Psychopharmacol. 2009 Nov;23(8):875-82. doi: 10.1177/0269881108093586. Epub 2008 Jun 26.

PMID:
18583440
44.

Combined antipsychotic treatment involving clozapine and aripiprazole.

Englisch S, Zink M.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1386-92. doi: 10.1016/j.pnpbp.2008.02.010. Epub 2008 Feb 29. Review.

PMID:
18407391
45.

Augmentation of clozapine with valproic Acid for clozapine-induced obsessive-compulsive symptoms.

Zink M, Englisch S, Knopf U, Kuwilsky A, Dressing H.

Pharmacopsychiatry. 2007 Sep;40(5):202-3. No abstract available.

PMID:
17874353
46.

Detection and molecular typing of Borrelia burgdorferi sensu lato in Ixodes ricinus ticks and in different patient samples from southwest Germany.

Schaarschmidt D, Oehme R, Kimmig P, Hesch RD, Englisch S.

Eur J Epidemiol. 2001;17(12):1067-74.

PMID:
12530764
47.

DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R.

Cancer Res. 2001 Feb 15;61(4):1659-65.

48.

New missense mutation (G626V) in the predicted selectivity filter of the HERG channel associated with familial long QT syndrome.

Jahr S, Lewalter T, Hesch RD, Lüderitz B, Englisch S.

Hum Mutat. 2000 Jun;15(6):584. No abstract available.

PMID:
10862104
49.

Possible drug-induced thrombocytopenia secondary to tiagabine.

Willert C, Englisch S, Schlesinger S, Runge U.

Neurology. 1999 Mar 10;52(4):888. No abstract available.

PMID:
10078753
50.

[QT syndrome: new diagnostic possibilities].

Lewalter T, Englisch S, Jahr S, Schumacher B, Jung W, Hesch RD, Lüderitz B.

Z Kardiol. 1998 Jul;87(7):517-21. Review. German.

PMID:
9744062

Supplemental Content

Loading ...
Support Center